Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 7/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284215 | 1.00 | TACR3 (0.70) | TACR3CA12CA1CA2CA9 | |
| SCHEMBL30284342 | 0.91 | TACR3 (0.58) | TACR3CA12CA1CA2CA9 | |
| SCHEMBL6452631 | 0.83 | TACR3 (1.00) | TACR3CYP3A4PTGER4 | |
| SCHEMBL2373465 | 0.80 | KDM4E (0.69) | CA12CA1CA2CA9MAPT | |
| SCHEMBL8617534 | 0.78 | CA12 (0.64) | TACR3CA12CA1CA2CA9 | |
| SCHEMBL2372402 | 0.78 | CA12 (0.63) | TACR3CA12CA1CA2CA9 | |
| SCHEMBL30690068 | 0.78 | DHODH (0.63) | TACR3CA12CA1CA2CA9 | |
| SCHEMBL28984340 | 0.78 | TRPV4 (0.60) | TACR3TRPV4CYP3A4 | |
| SCHEMBL25191932 | 0.77 | TRPV4 (0.59) | TACR3TRPV4PDE2APTGER4 | |
| SCHEMBL17268111 | 0.77 | TACR3 (0.82) | TACR3CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018165034-A1 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |